News coverage about Recro Pharma (NASDAQ:REPH) has trended somewhat positive on Wednesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Recro Pharma earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 46.0605851947031 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
REPH has been the topic of a number of research reports. Zacks Investment Research upgraded Recro Pharma from a “hold” rating to a “buy” rating and set a $9.75 price target on the stock in a research report on Wednesday, November 15th. Oppenheimer initiated coverage on Recro Pharma in a research report on Tuesday, February 13th. They set an “outperform” rating and a $19.00 price target on the stock. UBS Group initiated coverage on Recro Pharma in a research report on Tuesday, February 13th. They set an “outperform” rating on the stock. CIBC initiated coverage on Recro Pharma in a research report on Wednesday, February 14th. They set an “outperform” rating and a $19.00 price target on the stock. Finally, ValuEngine upgraded Recro Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $13.75.
Recro Pharma (REPH) traded up $0.71 on Wednesday, reaching $11.09. The company had a trading volume of 332,579 shares, compared to its average volume of 199,767. Recro Pharma has a 12-month low of $5.81 and a 12-month high of $11.57. The company has a current ratio of 1.75, a quick ratio of 1.55 and a debt-to-equity ratio of 1.86. The firm has a market cap of $194.82, a PE ratio of -4.15 and a beta of -0.59.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.